Between 33,000 and 42,200 European patients are expected to experience delayed access to clinical trials over the next 3 years as a result of IVDR.

Join us and learn how ARCs experts, supported by our digital regulatory navigation tools, can accelerate your clinical performance study approval.

What you’ll learn:

• How the regulatory landscape has changed in key geographic markets and how it impacts device study approvals.
• How to minimise the impact of IVDR on your precision medicine trials.
• Strategies to expedite patient screening and keeping your clinical development programmes on track
• Spotlight on ARC360, your online regulatory navigator to save you valuable time and resources.